11.13.25 -- Navigating The Complexities Of Small Molecule Production With The Right CDMO Partner

As oncology therapies become increasingly targeted, the use of Highly Potent Active Pharmaceutical Ingredients (HPAPIs) and Antibody-Drug Conjugates (ADCs) is accelerating. Explore their growing role to highlight manufacturing challenges, safety protocols, and opportunities.

Sustainability has become a critical focus in pharmaceutical manufacturing, especially in the production of APIs, which contribute significantly to global emissions. As the industry faces increasing scrutiny and regulatory demands, the need for more sustainable practices in small molecule API manufacturing has never been more urgent.

Incorporating phase-specific quality standards ensures compliance with GMP at all stages. This risk-based approach addresses late-stage quality needs to support overall development objectives. Discover how collaborating with an experienced CDMO offers valuable expertise in setting expectations and efficiently managing development timelines.

Examine the importance of a client-focused approach in the journey to commercialization with case studies that showcase the value of partnering with a CDMO for API and HPAPI development to overcome challenges in delivering new medicines to patients efficiently.

Ensure the success of your Small Molecule program with a reliable and committed CDMO that meets your needs and navigates complexity with you. With 35+ years of experience, expert capabilities, and capacity, MilliporeSigma is the partner to support you every step of the way.